Do Symptom Domains Have Similar Cellular Underpinnings Across Psychiatric Diagnoses: Evidence from 3D Hippocampal MR Spectroscopy
Preprint
Abstract
Introduction: The NIMH Research Domain Criteria (RDoC) posits similar cellular pathologies for particular symptom domains across diagnostic categories. Conversely, knowledge that these differ could advance treatment discovery, especially for affective and non-affective psychoses, as studies usually intermix them. Methods: We tested this by comparing metabolite biomarker concentrations for cellular pathologies from whole hippocampal proton magnetic spectroscopic imaging ( 1 H MRSI) with symptoms from the original and five factor PANSS, and the Hamilton Depression and Young Mania Scales. Participants were 26 healthy controls; 22 non-psychotic affective cases (NP-aff); and 33 with psychosis (including 20 schizophrenia (Scz) and 13 affective psychosis (aff-P) cases). Results: PANSS activation factor was related to reductions in all cellular component biomarkers in Scz, including glia, membrane turnover, neural integrity, glutaminergic neurotransmission, and energy metabolism (p’s<.05), but only to energy metabolism in NP-aff (p=.03). Biomarkers for mood symptoms also varied across categories, suggesting gliosis for mania and depression in HC (p’s≤.025), but increased membrane turnover for mania in aff-P (p=.015), and decreased neural integrity and energy metabolism for depression in Scz (p’s<.05). In contrast, negative symptoms and autistic preoccupation were related to reduced glia in both NP-aff and aff-P (p’s<.05). Autistic preoccupation in Scz was related to both reduced glia and membrane turnover (p’s<.05). Only Scz showed a significant finding for positive symptoms, specifically reduced membrane turnover (p=.018). Discussion: These results suggest both distinct and similar cellular pathologies for symptoms across diagnoses, including affective and non-affective psychoses. The differences support categorizing disorders and stratifying different psychoses in research rather than transdiagnostic approaches.Keywords
Funding Information
- National Institute of Mental Health (1R01MH110418-01A1)
- National Institute of Biomedical Imaging and Bioengineering (P41 EB017183)
- National Institute of Biomedical Imaging and Bioengineering (U24 EB02898)
This publication has 75 references indexed in Scilit:
- Methodological consensus on clinical proton MRS of the brain: Review and recommendationsMagnetic Resonance in Medicine, 2019
- The role of gray and white matter segmentation in quantitative proton MR spectroscopic imagingNMR in Biomedicine, 2012
- MR Spectroscopy and Spectroscopic Imaging of the Brain2010
- Reduced Prefrontal Glutamate/Glutamine and γ-Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance SpectroscopyArchives of General Psychiatry, 2007
- Optimizing the efficiency of high‐field multivoxel spectroscopic imaging by multiplexing in space and timeMagnetic Resonance in Medicine, 2006
- Reducing voxel bleed in hadamard-encoded MRI and MRSMagnetic Resonance in Medicine, 2006
- Issues of spectral quality in clinical 1H‐magnetic resonance spectroscopy and a gallery of artifactsNMR in Biomedicine, 2004
- Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imagingMagnetic Resonance in Medicine, 1998
- Diagnostic Interview for Genetic StudiesArchives of General Psychiatry, 1994
- Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopyMagnetic Resonance in Medicine, 1993